Loading...
OTCM
SDZXF
Market cap36bUSD
Jun 17, Last price  
85.45USD
1D
4.85%
1Q
7.01%
IPO
207.71%
Name

Sandoz Group AG

Chart & Performance

D1W1MN
OTCM:SDZXF chart
P/E
P/S
4.05
EPS
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
%
Revenues
9.12b
-8.60%
9,035,097,3978,794,328,5908,859,184,0189,979,000,0009,121,073,997
Net income
0k
-100.00%
433,639,621830,153,899-22,86177,000,0000
CFO
656m
+81.22%
1,030,598,0611,237,916,7181,168,044,637362,000,000656,000,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Operating globally, Sandoz Group AG specializes in the development, production, and distribution of generic medications and biosimilar products. The company's portfolio includes the creation and sale of finished dosage forms for small molecule pharmaceuticals, often supplied to other entities. Sandoz is also a significant player in the biotechnology sector, providing protein-based products such as biosimilars and offering specialized manufacturing services within this field. Furthermore, it supplies anti-infective products, including active pharmaceutical ingredients (APIs) and intermediates, with a strong emphasis on antibiotics. Established in 1886, Sandoz maintains its headquarters in Rotkreuz, Switzerland.
URL
IPO date
Oct 04, 2023
Employees
Domiciled in
CH
Incorporated in
CH

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT